Cited by 1,858HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancerBreast Cancer Treatment Studies

The DOI matches its Crossref record; 65 of the 70 references it cites were found in a registry or an index.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Open access

Nagata, Yoichi, Lan, Keng-Hsueh, Zhou, Xiaoyan, Tan, Ming, Esteva, Francisco J., Sahin, Aysegul A., Klos, Kristine S., Li, Ping, Monia, Brett P., Nguyen, Nina T., Hortobagyi, Gabriel N., Hung, Mien-Chie, Yu, Dihua·2004·Cancer Cell

DOI 10.1016/j.ccr.2004.06.022

Open this paper in CoChat — free account Open PDF

Abstract

The ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable therapeutic efficacy in certain patients with ErbB2-overexpressing tumors. The overall trastuzumab response rate, however, is limited and what determines trastuzumab response is poorly understood. Here we report that PTEN activation contributes to trastuzumab's antitumor activity. Trastuzumab treatment quickly increased PTEN membrane localization and phosphatase activity by reducing PTEN tyrosine phosphorylation via Src inhibition. Reducing PTEN in breast cancer cells by antisense oligonucleotides conferred trastuzumab resistance in vitro and in vivo. Patients with PTEN-deficient breast cancers had significantly poorer responses to trastuzumab-based therapy than those with normal PTEN. Thus, PTEN deficiency is a powerful predictor for trastuzumab resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2004.06.022

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,018
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,637
The Multiple Roles of PTEN in Tumor Suppression
Di Cristofano, A., & Pandolfi, P. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80674-1 · Cited by 1,182
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886

Flagged first, then by citations

Show all 70 references

5 of the 70 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Petit, 1997, Neutralizing antibodies against epidermal growth factor and ErbB2/neu receptor tyrosine kinase down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo, Am. J. Pathol., 151, 1523

Sorted by citations

Items 801–900 of 1,001

UBE2S promotes cell chemoresistance through PTEN-AKT signaling in hepatocellular carcinoma
Gui, L., Zhang, S., Xu, Y., Zhang, H., Zhu, Y., & Kong, L. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00750-3 · Cited by 36
An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer
Elshazly, A. M., & Gewirtz, D. A. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.09 · Cited by 35
Predictive markers in breast cancer – the future
Faratian, D., & Bartlett, J. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02896.x · Cited by 36
Inhibition of c-Met as a Therapeutic Strategy for Esophageal Adenocarcinoma
Watson, G. A., Zhang, X., Stang, M. T., Levy, R. M., de Oliveira, P. E. Q., Gooding, W. E., Christensen, J. G., & Hughes, S. J. (2006) · Neoplasia · doi:10.1593/neo.06499 · Cited by 36
Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab
da Costa, A. A. B. A., Costa, F. D., Ribeiro, A. R., Guimarães, A. P., Chinen, L. T. D., Lopes, C. A. P., & de Lima, V. C. C. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-014-0707-1 · Cited by 37
Mechanisms of resistance to EGFR inhibitors
Bianco, R., Gelardi, T., Damiano, V., Ciardiello, F., & Tortora, G. (2006) · Targeted Oncology · doi:10.1007/s11523-006-0038-x · Cited by 36
The molecular genetics of breast cancer and targeted therapy.
Suter, R., & Marcum, J. A. (2007) · PubMed Central · Cited by 36
The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis
Ibrahim, E. M., Kazkaz, G. A., Al-Mansour, M. M., & Al‐Foheidi, M. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3480-6 · Cited by 35
Clinical Significance of PTEN and p-Akt Co-Expression in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies
Fabi, A., Metro, G., Benedetto, A. D., Nisticò, C., Vici, P., Melucci, E., Antoniani, B., Perracchio, L., Sperduti, I., Milella, M., et al. (2010) · Oncology · doi:10.1159/000312656 · Cited by 35
Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells
Xu, Y., Benlimame, N., Su, J., He, Q., & Alaoui‐Jamali, M. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604901 · Cited by 39
Genetically engineered mouse models of PI3K signaling in breast cancer
Klarenbeek, S., van Miltenburg, M. H., & Jonkers, J. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.003 · Cited by 36
Lapatinib, a Dual-Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2-Amplified Breast Cancer: From Bench to Bedside
Tsang, R. Y., Sadeghi, S., & Finn, R. S. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s3783 · Cited by 35
Sequestosome 1/p62 facilitates HER2-induced mammary tumorigenesis through multiple signaling pathways
Cai-McRae, X., Zhong, H., & Karantza, V. (2014) · Oncogene · doi:10.1038/onc.2014.244 · Cited by 36
Immunohistochemical profiles of brain metastases from breast cancer
Yonemori, K., Tsuta, K., Shimizu, C., Hatanaka, Y., Hashizume, K., Ono, M., Nakanishi, Y., Hasegawa, T., Miyakita, Y., Narita, Y., et al. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9654-x · Cited by 35
A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action
Damiano, V., Garofalo, S., Rosa, R., Bianco, R., Caputo, R., Gelardi, T., Merola, G., Racioppi, L., Garbi, C., Kandimalla, E. R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1599 · Cited by 37
Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Błajecka, K., Borgström, A., & Arcaro, A. (2011) · Current Drug Targets · doi:10.2174/138945011795677773 · Cited by 34
Cancer oxidative stress and dietary antioxidants
Preedy, V. R. (2014) · doi:10.1016/b978-0-12-405205-5.01001-1 · Cited by 35
Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
Kong, X., Zhang, K., Wang, X., Yang, X. C., Li, Y., Zhai, J., Xing, Z., Qi, Y., Gao, R., Feng, X., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s194137 · Cited by 35
Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem
Wahdan-Alaswad, R. S., Liu, B., & Thor, A. D. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.92 · Cited by 35
Targeting Her-2/neu in Breast Cancer: As Easy as This!
Azim, H. A., & Azim, H. A. (2008) · Oncology · doi:10.1159/000151362 · Cited by 35
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology
Jacobi, N., Seeboeck, R., Hofmann, E., & Eger, A. (2017) · Cancers · doi:10.3390/cancers9040033 · Cited by 36
The Role of Trastuzumab in Early Stage Breast Cancer: Current Data and Treatment Recommendations
Lin, A., & Rugo, H. S. (2007) · Current Treatment Options in Oncology · doi:10.1007/s11864-007-0008-2 · Cited by 35
Four-and-a-half-LIM protein 1 down-regulates estrogen receptor α activity through repression of AKT phosphorylation in human breast cancer cell
Zhang, F., Feng, F., Yang, P., Li, Z., You, J., Xie, W., Gao, X., & Yang, J. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.11.002 · Cited by 34
First-line chemotherapy with or without biologic agents for metastatic breast cancer
Andreetta, C., Minisini, A. M., Miscoria, M., & Puglisi, F. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.01.007 · Cited by 34
ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
Ebbing, E. A., Medema, J. P., Damhofer, H., Meijer, S. L., Krishnadath, K. K., Henegouwen, M. I. V. B., Bijlsma, M. F., & van Laarhoven, H. W. M. (2016) · Oncotarget · doi:10.18632/oncotarget.7200 · Cited by 34
Targeting HER 2 in patient‐derived xenograft ovarian cancer models sensitizes tumors to chemotherapy
Harris, F. R., Zhang, P., Yang, L., Hou, X., Leventakos, K., Weroha, S. J., Vasmatzis, G., & Kovtun, I. V. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12414 · Cited by 34
Targeting HER2 genomic alterations in non-small cell lung cancer
Zeng, J., Ma, W., Young, R. B., & Li, T. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.04.001 · Cited by 37
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer
André, F., Nahta, R., Conforti, R., Boulet, T., Aziz, M., Yuan, L. X. H., Meslin, F., Spielmann, M., Tomasic, G., Pusztai, L., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm429 · Cited by 34
The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes
Li, X., Zhang, R., Liu, Z., Li, S., & Xu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.15690 · Cited by 34
DNA tumor viruses — the spies who lyse us
O’Shea, C. C. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.010 · Cited by 34
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
Toomey, S., Eustace, A. J., Fay, J., Sheehan, K. M., Carr, A., Milewska, M., Madden, S. F., Teiserskiene, A., Kay, E. W., O’Donovan, N., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0883-9 · Cited by 34
Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms
Shi, H., Zhang, W., Zhi, Q., & Jiang, M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5467-2 · Cited by 36
Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy
Saintigny, P., Mitani, Y., Pytynia, K. B., Ferrarotto, R., Roberts, D. B., Weber, R. S., Kies, M. S., Maity, S. N., Lin, S.-H., & El‐Naggar, A. K. (2018) · Cancer · doi:10.1002/cncr.31600 · Cited by 33
Cancer of the Breast
Henry, N. L., Shah, P. D., Haider, I., Freer, P. E., Jagsi, R., & Sabel, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00088-8 · Cited by 37
Measurement of Glut-1 Expression Using Tissue Microarrays to Determine a Race Specific Prognostic Marker for Breast Cancer
Stackhouse, B. L., Williams, H. C., Berry, P., Russell, G. B., Thompson, P., Winter, J. L., & Kute, T. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-5158-y · Cited by 33
Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues
Bria, E., Cuppone, F., Milella, M., Verma, S., Carlini, P., Nisticò, C., Vaccaro, V., Rossi, A., Tonini, G., Cognetti, F., et al. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14728220802517935 · Cited by 33
Regulation of the Interaction between Protein Kinase C-related Protein Kinase 2 (PRK2) and Its Upstream Kinase, 3-Phosphoinositide-dependent Protein Kinase 1 (PDK1)
Dettori, R., Sonzogni, S. V., Meyer, L., Lopez-Garcia, L. A., MORRICE, N. A., Zeuzem, S., Engel, M., Piiper, A., Neimanis, S., Frödin, M., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.051151 · Cited by 32
Assessment of PTEN tumor suppressor activity in nonmammalian models: the year of the yeast
Cid, V. J., Rodríguez‐Escudero, I., Andrés‐Pons, A., Mateo, C. R., Gil, Á., den Hertog, J., Molina, M., & Pulido, R. (2008) · Oncogene · doi:10.1038/onc.2008.240 · Cited by 33
Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies.
Luís, M., Tavares, A., Carvalho, L. S., Lara-Santos, L., Araújo, A., & de Mello, R. D. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i38.6383 · Cited by 32
Treatment strategy for HER2-positive breast cancer
Mukai, H. (2010) · International Journal of Clinical Oncology · doi:10.1007/s10147-010-0107-0 · Cited by 33
Oral Ridaforolimus Plus Trastuzumab for Patients With HER2+ Trastuzumab-Refractory Metastatic Breast Cancer
Seiler, M., Ray-Coquard, I. L., Melichar, B., Yardley, D. A., Wang, R. X., Dodion, P. F., & Lee, M. A. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.07.008 · Cited by 33
The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
Dieras, V. C., & Bachelot, T. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0287-4 · Cited by 32
Presence of HER4 associates with increased sensitivity to Herceptin™ in patients with metastatic breast cancer
Sassen, A. W., Diermeier‐Daucher, S., Sieben, M., Ortmann, O., Hofstaedter, F., Schwarz, S., & Brockhoff, G. (2009) · Breast Cancer Research · doi:10.1186/bcr2339 · Cited by 32
Inhibiting PI3K as a therapeutic strategy against cancer
Paz-Ares, L. G., Blanco‐Aparicio, C., García‐Carbonero, R., & Carnero, A. (2009) · Clinical & Translational Oncology · doi:10.1007/s12094-009-0407-x · Cited by 31
Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis
Taha, M. O., Al-Sha’er, M. A., Khanfar, M. A., & Al-Nadaf, A. H. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.056 · Cited by 32
Survival of HER2-Positive Breast Cancer Cells: Receptor Signaling to Apoptotic Control Centers
Fink, M. Y., & Chipuk, J. E. (2013) · Genes & Cancer · doi:10.1177/1947601913488598 · Cited by 32
Mechanisms of Resistance to HER2 Target Therapy
Tortora, G. (2011) · JNCI Monographs · doi:10.1093/jncimonographs/lgr026 · Cited by 32
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies
Chien, A. J., Cockerill, A., Fancourt, C., Schmidt, E. V., Moasser, M. M., Rugo, H. S., Melisko, M., Ko, A. H., Kelley, R. K., Korn, W. M., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3701-7 · Cited by 32
PTEN Deletion Leads to Up-regulation of a Secreted Growth Factor Pleiotrophin
Li, G., Hu, Y., Huo, Y., Liu, M., Freeman, D., Gao, J., Liu, X., Wu, D.-C., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512509200 · Cited by 32
PTEN, PTENP1, microRNAs, and ceRNA Networks: Precision Targeting in Cancer Therapeutics
Travis, G., McGowan, E. M., Simpson, A. M., Marsh, D. J., & Nassif, N. T. (2023) · Cancers · doi:10.3390/cancers15204954 · Cited by 31
Nerves at Play: The Peripheral Nervous System in Extracranial Malignancies
Vermeer, P. D., Restaino, A. C., Barr, J. L., Yaniv, D., & Amit, M. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0397 · Cited by 35
Analysis of the Molecular Networks in Androgen Dependent and Independent Prostate Cancer Revealed Fragile and Robust Subsystems
Tasseff, R. A., Nayak, S., Salim, S., Kaushik, P., Rizvi, N. F., & Varner, J. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008864 · Cited by 31
New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistance
Curigliano, G. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.06.006 · Cited by 31
Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy
Yonemori, K., Tsuta, K., Shimizu, C., Hatanaka, Y., Hashizume, K., Ono, M., Kouno, T., Ando, M., Tamura, K., Katsumata, N., et al. (2008) · Medical Oncology · doi:10.1007/s12032-008-9127-2 · Cited by 31
HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer
Chandran, V. I., Eppenberger‐Castori, S., Venkatesh, T., Vine, K. L., & Ranson, M. (2015) · Oncoscience · doi:10.18632/oncoscience.146 · Cited by 29
Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer
Bianchi, A. S., Bencardino, K. B., Nicolantonio, F. D., Pozzi, F., Funaioli, C., Gambi, V., Arena, S., Martini, M., Lamba, S., Cassingena, A., et al. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0138-5 · Cited by 31
High Plasma Fibrinogen is Correlated With Poor Response to Trastuzumab Treatment in HER2 Positive Breast Cancer
Liu, Y., Lü, Q., Liang, J.-W., Xia, Y., Zhang, W., Hu, B., Shang, F., Ji, Y.-R., Wang, J., Wang, Q., et al. (2015) · Medicine · doi:10.1097/md.0000000000000481 · Cited by 31
Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.
Dey, N., Sun, Y., Carlson, J. H., Wu, H., Lin, X., Leyland-Jones, B. R., & De, P. K. (2016) · PubMed Central · Cited by 31
Pyrotinib combined with CDK4/6 inhibitor in HER2‐positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients
Chen, Z., Xu, Y., Gong, J., Kou, F., Zhang, M., Tian, T., Zhang, X., Zhang, C., Li, J., Li, Z., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.148 · Cited by 31
Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
Leo, A. D. (2010) · Cancer Management and Research · doi:10.2147/cmar.s8951 · Cited by 31
Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy
Coughlin, C. M., Johnston, D. S., Strahs, A. L., Burczynski, M. E., Bacus, S. S., Hill, J. E., Feingold, J. M., Zacharchuk, C., & Berkenblit, A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1108-4 · Cited by 31
Mechanisms of resistance to ErbB-targeted cancer therapeutics
Wang, Q., & Greene, M. I. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36260 · Cited by 31
Identification of prolidase as a high affinity ligand of the ErbB2 receptor and its regulation of ErbB2 signaling and cell growth
Yang, L., Li, Y., & Zhang, Y. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.187 · Cited by 31
Targeting HER2 Positive Breast Cancer with Chemopreventive Agents
Wahler, J., & Suh, N. (2015) · Current Pharmacology Reports · doi:10.1007/s40495-015-0040-z · Cited by 31
Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro
Festuccia, C., Gravina, G. L., Biordi, L. A., D’Ascenzo, S., Dolo, V., Ficorella, C., Ricevuto, E., & Tombolini, V. (2009) · The Prostate · doi:10.1002/pros.20995 · Cited by 31
Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: a Meta-analysis
Shen, K., Ma, X., Zhu, C., Wu, X. Y., & Jia, H. (2016) · Scientific Reports · doi:10.1038/srep23262 · Cited by 31
Predictive Biomarkers in the Treatment of Her2-Positive Breast Cancer: An Ongoing Challenge
Triulzi, T., Bianchi, G., & Tagliabue, E. (2016) · Future Oncology · doi:10.2217/fon-2015-0025 · Cited by 31
M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.
Machl, A. W., Wilker, E., Tian, H., Liu, X., Schroeder, P. E., Clark, A., & Huck, B. R. (2016) · PubMed Central · Cited by 31
Negative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing Field
Ledda, F., & Paratcha, G. (2007) · Biomarker Insights · doi:10.1177/117727190700200029 · Cited by 34
Molecular Predictive Factors in Patients Receiving Trastuzumab-Based Chemotherapy for Metastatic Disease
Robinson, A. G., Turbin, D. A., Thomson, T., Yorida, E., Ellard, S. L., Bajdik, C. D., Huntsman, D. D., & Gelmon, K. A. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.038 · Cited by 31
The PTEN and ATM axis controls the G1/S cell cycle checkpoint and tumorigenesis in HER2-positive breast cancer
Bassi, C., Fortin, J., Snow, B. E., Wakeham, A. C., Ho, J., Haight, J., You-Ten, A. J., Cianci, E., Buckler, L. N., Gorrini, C., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00799-8 · Cited by 30
An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer
Sueta, A., Yamamoto, Y., Yamamoto‐Ibusuki, M., Hayashi, M., Takeshita, T., Yamamoto, S., & Iwase, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116054 · Cited by 30
miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer
Nielsen, B. S., Balslev, E., Poulsen, T. S., Nielsen, D. L., MÃ¸ller, T., Mortensen, C. E., Holmstrøm, K., & Høgdall, E. V. S. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00207 · Cited by 31
Molecular Predictors of Response to Therapy for Breast Cancer
Galanina, N., Bossuyt, V., & Harris, L. N. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318212dee3 · Cited by 30
Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival
Pande, M., Bondy, M. L., Do, K.-A., Şahin, A. A., Ying, B., Mills, G. B., Thompson, P. A., & Brewster, A. M. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3081-9 · Cited by 29
Molecular Pathways: PI3K Pathway Phosphatases as Biomarkers for Cancer Prognosis and Therapy
Chen, M., Nowak, D. G., & Trotman, L. C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3680 · Cited by 30
Recent Progress in Mouse Models for Tumor Suppressor Genes and its Implications in Human Cancer
Inoue, K., Fry, E. A., & Taneja, P. (2013) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s10358 · Cited by 30
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone
Xu, B., Guan, Z., Shen, Z., Tong, Z., Jiang, Z., Yang, J., DeSilvio, M., Russo, M., Leigh, M., & Ellis, C. E. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0405-y · Cited by 30
When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase
Brix, D. M., Clemmensen, K. K. B., & Kallunki, T. (2014) · Cells · doi:10.3390/cells3010053 · Cited by 32
Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
Jernström, S., Hongisto, V., Leivonen, S., Due, E. U., Tadele, D. S., Edgren, H., Kallioniemi, O., Perälä, M., Mælandsmo, G. M., & Sahlberg, K. K. (2017) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s115600 · Cited by 32
Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling
Chen, Z., Sun, T., Yang, Z., Zheng, Y., Yu, R., Wu, X., Yan, J., Shao, Y. W., Shao, X., Cao, W., et al. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1079 · Cited by 29
Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy
Zhang, S., Wang, Y., Wang, Y., Peng, J., Yuan, C., Zhou, L., Xu, S., Lin, Y., Du, Y., Yang, F., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00631 · Cited by 34
PKC-mediated phosphorylation and activation of the MEK/ERK pathway as a mechanism of acquired trastuzumab resistance in HER2-positive breast cancer
Scerri, J., Scerri, C. A., Schäfer-Ruoff, F., Fink, S., Templin, M. F., & Grech, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1010092 · Cited by 30
Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer.
Mayer, I. A. (2013) · PubMed · Cited by 30
Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy.
Nawa, M., Osada, S., Morimitsu, K., Nonaka, K., Futamura, M., Kawaguchi, Y., & Yoshida, K. (2012) · PubMed · Cited by 30
The promise of mTOR inhibitors in the treatment of colorectal cancer
Kim, D.-D., & Eng, C. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.721353 · Cited by 31
Trastuzumab and Antiestrogen Therapy
Ocaña, A., Cruz, J. J., & Pandiella, A. (2006) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000190274.00570.0a · Cited by 30
Clinical Implications for Girdin Protein Expression in Breast Cancer
Ling, Y., Jiang, P., Cui, S.-P., Ren, Y., Zhu, S., Yang, J., Du, J., Zhang, Y., Liu, J., & Zhang, B. (2011) · Cancer Investigation · doi:10.3109/07357907.2011.568568 · Cited by 29
A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response
Xiao, Z., Carrasco, R. A., Schifferli, K. P., Kinneer, K., Tammali, R., Chen, H., Rothstein, R., Wetzel, L. K., Yang, C., Chowdhury, P. S., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0555 · Cited by 29
At the crossroads of cancer stem cells and targeted therapy resistance
Wang, A., Qu, L., & Wang, L. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.10.039 · Cited by 31
Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts
Braña, I., Pham, N., Kim, L., Sakashita, S., Li, M., Ng, C., Wang, Y., Loparco, P., Sierra, R. J., Wang, L. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19109 · Cited by 29
Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy
Dong, Z., Huang, Z., Li, S., Wang, Y., Yao, Y., Yang, X., & Xu, X. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.021 · Cited by 30
Targeting Receptor Tyrosine Kinases in Cancer
Köstler, W. J., & Zielinski, C. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2_10 · Cited by 26
Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma
Végran, F., Boidot, R., Coudert, B. P., Fumoleau, P., Arnould, L., Garnier, J., Causeret, S., Fraise, J., Dembélé, D., & Lizard‐Nacol, S. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605310 · Cited by 29
Somatic pharmacogenomics in cancer
Ikediobi, O. N. (2008) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.8 · Cited by 29
Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors
Şahin, Ö., Wang, Q., Brady, S. W., Ellis, K., Wang, H., Chang, C., Zhang, Q., Priya, P., Zhu, R., Wong, S. T. C., et al. (2014) · Cell Research · doi:10.1038/cr.2014.37 · Cited by 29
Cyr61 as mediator of Src signaling in triple negative breast cancer cells
Sánchez-Bailón, M. P., Calcabrini, A., Mayoral-Varo, V., Molinari, A., Wagner, K., Pérez‐Losada, J., Ciordia, S., Albar, J. P., & Martín-Pérez, J. (2015) · Oncotarget · doi:10.18632/oncotarget.3760 · Cited by 29
Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors
Quattrone, A., Woźniak, A., Dewaele, B., Floris, G., Vanspauwen, V., Looy, T. V., Schöffski, P., Rutkowski, P. L., Sciot, R., & Dêbiec‐Rychter, M. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.53 · Cited by 28
Targeted therapies in breast cancer
WICKI, A. N., & Rochlitz, C. F. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13550 · Cited by 31
Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α
Serdar, C. C., Cokol, M., Cingöz, S., Tasan, I., Öztürk, M., & Yağcı, T. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-450 · Cited by 28

Authors: Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., Hortobagyi, G. N., Hung, M.-C., & Yu, D.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Ionis Pharmaceuticals (United States) (US)
Corresponding author: Yu, Dihua
ORCID: Lan, Keng-Hsueh
Zhou, Xiaoyan
Tan, Ming
Esteva, Francisco J.
Li, Ping
Monia, Brett P.
Hung, Mien-Chie
Yu, Dihua
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2004-08
Volume: 6
Issue: 2
Pages: 117-127
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2004.06.022
OpenAlex: W2059411043
Cited by: 1,858
References: 70
Citations by year: 2026: 19 · 2025: 29 · 2024: 35 · 2023: 82 · 2022: 52 · 2021: 50 · 2020: 60 · 2019: 56 · 2018: 66 · 2017: 68 · 2016: 88 · 2015: 109 · 2014: 119 · 2013: 125 · 2012: 123
FWCI: 43.34
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3272 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ca060488-09)
National Cancer Institute (P01CA099031, 2R01-CA60488, P30CA016672)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: PTEN, trastuzumab, trastuzumab resistance, ERBB2, HER2-positive breast cancer, Src kinase inhibition, PI3K inhibitors, predictive biomarkers, antisense oligonucleotides
MeSH terms: Trastuzumab, Phosphoinositide-3 Kinase Inhibitors, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Enzyme Activation, Enzyme Inhibitors, Female, Humans, Mice, Nude, Neoplasm Transplantation, Phosphoric Monoester Hydrolases, Proto-Oncogene Proteins, Genes, Tumor Suppressor, Oligonucleotides, Antisense, Protein Serine-Threonine Kinases, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, src-Family Kinases, Phosphatidylinositol 3-Kinases, Tumor Suppressor Proteins, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Mice, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks